AstraZeneca Gains FDA Approval for Camizestrant Combo in ESR1-Mutated Advanced Breast Cancer

The U.S. FDA has approved AstraZeneca’s Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adults with hormone receptor-positive, HER2-negative, advanced breast cancer upon ESR1 mutation detection during existing therapies, as per the press release by The US FDA. 

New Approval for Etcamah Combination Treatment 

On September 4, 2026, the FDA granted accelerated approval for AstraZeneca’s Etcamah in combination with CDK4/6 inhibitors like abemaciclib, palbociclib, or ribociclib. This treatment targets adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer having ESR1 mutations. 

ESR1 mutations manifest as resistance in some cancer cases treated with aromatase inhibitors, a common endocrine therapy. Initially rare at under 5% upon HR-positive metastatic diagnosis, these mutations rise to 40% following disease progression with aromatase inhibitors. 

Mechanism of Approval 

The accelerated approval is based on progression-free survival, measured from the detection of the resistance mutation. The FDA is requiring further studies to confirm clinical benefits. Acting FDA Commissioner Kyle Diamantas highlighted this approval as a critical step for patients facing treatment-resistant cancer stages. 

Confirmatory Studies and Diagnostic Tests 

Efficacy was cited from a clinical trial, showing a median progression-free survival of 16 months with Etcamah and CDK4/6 inhibitor versus 9.2 months with an aromatase inhibitor and CDK4/6 inhibitor. 

Read More: UltraTech Cement Share Price in Focus; To Deploy Over 600 Electric Trucks by December 2026! 

Introduction of Companion Diagnostic Device 

The FDA authorised the Guardant360 CDx test to identify ESR1 mutations in patients, allowing for precise matching of patients to the new treatment regimen. 

Prescription Notes and Safety Warnings 

Prescribing information includes warnings regarding irregular and slow heart rhythms, especially when combined with certain medications, and potential impact on unborn babies. Full details will be available on the FDA's database. 

Conclusion 

The FDA's accelerated approval of AstraZeneca’s Etcamah in combination with a CDK4/6 inhibitor represents an important advance for treating patients with hormone receptor-positive, HER2-negative breast cancer that shows resistance due to ESR1 mutations, shown to extend progression-free survival compared to previous treatments. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.